Drug Database
BE

benzodiazepine

✓ Approved

Valenta Pharm · Small Molecule · Small Molecule

What is benzodiazepine?

benzodiazepine is a small molecule developed by Valenta Pharm. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyValenta Pharm
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved

Therapeutic Indications

benzodiazepine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersAnxiety✓ Approved

Related Research Articles

PubMedCureus2026-09-20

Post-Stroke Recrudescence During the Perioperative Period: Potential Roles of Anesthetic and Sedative Agents.

Fadel Mahdi M, Fadel Ali A, Jwaida Nataliah N, Berry Adam A et al.

Post-stroke recrudescence (PSR) is the transient reappearance of previously recovered focal neurologic deficits after a systemic or pharmacologic stressor, without evidence of a new cerebral infarction. In the perioperative setting, PSR can closely resemble acute ischemic stroke, residual anesthetic effects, seizure, or delirium, creating a significant diagnostic challenge. This narrative review examines the proposed mechanisms of PSR and evaluates the available evidence regarding anesthetic, sedative, and analgesic agents as potential triggers. Previously injured neural networks may remain vulnerable to disruptions in excitatory-inhibitory balance despite apparent clinical recovery. Human evidence is strongest for midazolam and broader benzodiazepine exposure, while evidence involving opioids, propofol, volatile anesthetics, and dexmedetomidine remains limited or indirect. Determining the independent effect of any single medication is difficult because surgery frequently involves simultaneous stressors, including hypotension, hypoxemia, infection, electrolyte abnormalities, pain, and sleep disruption. PSR typically reproduces the pattern of a patient's prior stroke deficits, is not associated with new diffusion-weighted imaging abnormalities, and improves after correction of the underlying trigger or resolution of medication effects. However, PSR remains a diagnosis of exclusion, and its consideration should not delay prompt evaluation for acute stroke. Recognition may be improved through clear preoperative documentation of baseline neurologic findings, comparison of postoperative deficits with the previous stroke syndrome, and early communication among anesthesiology, surgical, and neurology teams. Current evidence does not establish most anesthetic agents as independent causes of PSR, highlighting the need for prospective studies that document specific agents, doses, timing, concurrent perioperative stressors, and neurologic outcomes.

PubMedClinical neuropharmacology2026-09-18

Benzodiazepine-Sparing Alcohol Withdrawal Protocol Pilot in Postsurgical Head and Neck Cancer Patients.

Shapiro-Krew Anna P AP, Coulter Andrew A, Davies Marilyn M, Torbic Heather H et al.

Alcohol use disorder is associated with high rates of morbidity and mortality in hospitalized patients. Patients with head and neck cancer have rates of comorbid alcohol use as high as 30% to 60%. Traditionally, withdrawal is managed by assessing symptoms with the Clinical Institute Withdrawal Assessment (CIWA) and treating with benzodiazepines. Benzodiazepines perpetuate neurotransmitter dysregulation in alcohol withdrawal, but valproic acid can correct dysregulations of glutamic and GABAergic systems. We conducted an IRB-approved retrospective chart review of patients admitted from January 2019 to February 2020 who were admitted for head or neck cancer surgery and had concurrent diagnoses of alcohol use disorder. We reviewed cases of patients who received nonbenzodiazepine withdrawal treatments (gabapentin, valproic acid) and compared them to patients who received benzodiazepine tapers. In the benzodiazepine population, 60% of patients underwent active alcohol withdrawal. Of these, 66.7% were given as-needed benzodiazepines based on CIWA scores. In the benzodiazepine-sparing group, 50% received valproic acid and 50% received gabapentin. Only 1 had an elevated CIWA score above 8, and only 1 patient had a dose of lorazepam (for agitation). This preliminary data demonstrates improvement in outcomes, increased control over withdrawal symptoms, and minimization of episodes of agitation and rates of delirium. In patients with significant medical comorbidities, the utilization of a benzodiazepine-sparing protocol is protective against withdrawal. We have found benefit from proactive utilization of a benzodiazepine-sparing protocol versus a traditional CIWA-based reactive treatment model for alcohol withdrawal.

PubMedBMJ public health2026-09-18

Role of gender, age and rurality in benzodiazepine consumption in Catalonia, 2018-2022: a retrospective longitudinal drug utilisation study.

Barrera Aranda Belén B, Aznar-Lou Ignacio I, Peñarrubia-María María Teresa MT, Chilet Rosell Elisa E et al.

Benzodiazepines are among the most widely prescribed medications for numerous indications, but their adverse effects, misuse and consequences pose an increasing public health concern. This study analyses trends in benzodiazepine use in Catalonia from 2018 to 2022, focusing on differences by age, sex and rural-urban residence. A retrospective longitudinal drug utilisation study was conducted using the Information System for Research in Primary Care primary care database, including 6 992 261 individuals aged ≥15 years registered in Catalonia between 2018 and 2022. Drugs were classified according to the WHO's Anatomical Therapeutic Chemical system. Quantities dispensed were measured in defined daily doses (DDD) and expressed as DDD per 1000 inhabitants per day (DID) for each quarter. Data were stratified by age, sex and area of residence. Benzodiazepine consumption increased across all demographic groups between 2018 and 2022. Key findings showed significant disparities by sex, age and urban-rural area, exacerbated by the intersection of these factors. Rural women over 65 showed the highest usage levels (428 DID in 2022), while young adults experienced the largest proportional increases with an estimated average quarterly percentage change of 4.06 (95% CI 4.02 to 4.09) in women and 3.20 (95% CI 3.15 to 3.23) among men. No statistically significant structural break was detected at the onset of the COVID-19 pandemic, suggesting that observed fluctuations reflected the underlying temporal trend. The consistent rise in benzodiazepine consumption across all age groups in Catalonia highlights gaps in prevention and management strategies. Disparities linked to socioeconomic factors, gender roles, older age and area of residence underscore structural inequities affecting older adults, women and rural populations. These findings reflect a deep-rooted public health challenge in Spain, driven by pharmacological over-reliance and insufficient attention to the impact caused by social determinants of health. Addressing this requires coordinated and multidisciplinary reforms to tackle inequity and enhance societal well-being.

PubMedBritish journal of clinical pharmacology2026-09-18

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences.

Chaudhry Alvina A, Khan Muhammad Umair MU, Conway Barbara B, Hasan Syed Shahzad SS

Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID-19 and adverse outcomes on prescribing patterns in England remains uncertain. This study evaluates trends in BZD prescribing, costs, and safety outcomes and explores their socioeconomic associations. This population-level observational study analysed prescribing, cost and ADR data for 14 BZDs using national datasets. Prescribing rates were standardized per 100 000 population, fatality ratios were calculated, and regression models assessed yearly changes by drug, region, and pandemic phase. Socioeconomic influences on prescribing were analysed using a generalized additive model. Total BZD prescribing decreased from 15562.34 items per 100 000 population in 2020 to 12284.01 in 2025, a mean annual change of -4.3% (95% CI: -4.5% to -4.03%), largely because of reduced prescribing of diazepam, temazepam and chlordiazepoxide. Conversely, specialist-use agents increased, including clobazam (6.36% per year, 95% CI: 0.34% to 12.39%) and midazolam (1.03% per year, 95% CI: -1.30% to 3.37%). Ethnicity influenced deprivation-related prescribing patterns, indicating disparities beyond socioeconomic status. The average lifetime fatality ratio across all BZDs was 4.5 deaths per 100 reported cases, with oxazepam the highest (17.9), followed by lorazepam (9.1) and alprazolam (8.6). Benzodiazepine prescribing in England continues to decline, reflecting successful deprescribing policies. However, increasing specialist use, persistent inequities, and drug-specific safety and cost concerns highlight the need for cautious prescribing, enhanced pharmacovigilance and equitable access.

PubMedFrontiers in medicine2026-09-18

Perioperative cognitive dysfunction in bladder cancer patients, causal factors, and possible interventions.

Cicvaric Ana A, Glavas Tahtler Josipa J, Pavlovic Oliver O, Dias Celeste C et al.

Bladder cancer (BC) primarily necessitates surgical and oncological interventions; however, patients frequently encounter a substantial burden of perioperative neurocognitive disorders, which compromise clinical outcomes and treatment compliance. While individual risks are recognized, a comprehensive synthesis identifying the overlapping clinical determinants and promoters of this decline remains essential. This review aims to elucidate the specific mechanisms underlying perioperative cognitive impairment in surgical BC patients and highlight targeted preventive strategies. Evidence demonstrates that perioperative cognitive decline in this population is highly multifactorial. Key demographic and clinical predictors include advanced age and clinical frailty, which are compounded by chronic cerebral small vessel disease secondary to long-term tobacco smoking, hypertension, and metabolic diseases. Furthermore, surgical and procedural risks, such as frequent instrumentation and catheterization, are associated with bleeding and a higher incidence of recurrent urinary tract infections, which induce systemic inflammation and may precipitate acute disorientation or delirium. Anesthesia-related factors, including preoperative benzodiazepine use, intraoperative hypotension, prolonged anesthesia duration, and the omission of neuromuscular blockade reversal agents, significantly exacerbate post-surgical cognitive vulnerability. All these factors, with systemic inflammation, may cause cerebral hypoperfusion that precipitates delirium. Metabolic comorbidities, particularly diabetes mellitus, synergistically exacerbate infection risks, while psychological distress (severe anxiety and depression) and neurotoxic chemotherapy protocols serve as vital indicators of post-surgical cognitive vulnerability. Cognitive function heavily dictates urological care trajectories. Incorporating routine, structured preoperative cognitive and frailty screenings is imperative to risk-stratify patients, implement tailored pre-habilitation, and optimize both cognitive and oncological outcomes.

PubMedJournal of addiction medicine2026-09-18

Insights About Nitazene Use From Self-reported Experiences on Reddit Obtained Using Natural Language Processing.

Sompalle Pranav P, Perrone Jeanmarie J, Wightman Rachel R, Love Jennifer J et al.

Nitazenes are an emerging class of highly potent synthetic opioids not approved for clinical use. Knowledge of nitazene-associated practices and clinical effects remains limited. Reddit contains nitazene-related discussions describing self-reported experiences. We analyzed nitazene mentions to characterize these experiences. Nitazene-mentioning posts between 01/2019 and 10/2025 were extracted via natural language processing-based lexical filters, and a random sample of 293 mentions was qualitatively reviewed and annotated for themes consolidated via consensus discussion. Repeated findings more specific than themes were synthesized as subthemes, and a validated GPT-4o-based pipeline was applied to all mentions to forecast the theme distribution. A total of 31,638 mentions were extracted; frequency increased between 2022 and 2024 (mean 584 mentions/month, P<0.01 increase compared with 2019-2021's mean of 197 mentions/month). Ten themes were curated, with source (31.3%), potency and dose (26.5%), and uncertainty (25.9%) most prevalent in the annotated sample. Across the full dataset, automated characterization predicted that general experience (44.7%), general comment (37.9%), and potency and dose (27.6%) were the most prevalent thematic labels. Nine subthemes included information about counterfeit pills, withdrawal management difficulties, motivating factors for use, benzodiazepine adulteration, and vascular injury associated with intravenous administration. Increasing nitazene mentions on Reddit may reflect increasing interest and use. Thematic characterization identified patterns in nitazene use, effects, and distribution relevant to clinical practice and public health. Insights provided by subthemes align with laboratory potency assessments and emerging evidence from case series and health alerts. These findings can inform public health monitoring, overdose prevention, and clinical characterizations of nitazene use.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about benzodiazepine